Aptinyx Reports the Completion of Patient Enrollment of NYX-458 in P-II Study for Cognitive Impairment


The company completed the patient enrolment in the P-II study to evaluate the safety & cognitive benefits of NYX-458 (30mg) vs PBO in 99 patients with cognitive impairment associated with Parkinson’s disease & dementia with Lewy bodies. Enrolled patients have completed 12wk. treatment period & 30-day safety follow-up period
The study evaluates the overall safety & tolerability of NYX-458 along with the effects across multiple neurocognitive EPs focused on attention, memory & executive function. The results from the P-II study are expected in Q1’23
NYX-458 showed positive safety & tolerability profile in a P-I study while CNS exposures were consistent with exposures at efficacious preclinical dose levels

Ref: Businesswire | Image: Aptinyx